ZA200902187B - 8-Ethinylxanthine derivatives as selective A2A receptor antagonists - Google Patents

8-Ethinylxanthine derivatives as selective A2A receptor antagonists

Info

Publication number
ZA200902187B
ZA200902187B ZA200902187A ZA200902187A ZA200902187B ZA 200902187 B ZA200902187 B ZA 200902187B ZA 200902187 A ZA200902187 A ZA 200902187A ZA 200902187 A ZA200902187 A ZA 200902187A ZA 200902187 B ZA200902187 B ZA 200902187B
Authority
ZA
South Africa
Prior art keywords
ethinylxanthine
selective
derivatives
receptor antagonists
antagonists
Prior art date
Application number
ZA200902187A
Other languages
English (en)
Inventor
Mueller Christa
Hockemeyer Joerg
Tzvetkov Nikolay
Burbiel Joachim
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of ZA200902187B publication Critical patent/ZA200902187B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200902187A 2006-12-22 2009-03-26 8-Ethinylxanthine derivatives as selective A2A receptor antagonists ZA200902187B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026739A EP1939197A1 (fr) 2006-12-22 2006-12-22 Derivés de 8-éthinylxanthine comme antagonistes selectives du recepteur A2A

Publications (1)

Publication Number Publication Date
ZA200902187B true ZA200902187B (en) 2009-11-25

Family

ID=37733427

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902187A ZA200902187B (en) 2006-12-22 2009-03-26 8-Ethinylxanthine derivatives as selective A2A receptor antagonists

Country Status (12)

Country Link
US (1) US8044061B2 (fr)
EP (2) EP1939197A1 (fr)
CN (1) CN101631788A (fr)
AR (1) AR064657A1 (fr)
AU (1) AU2007338413A1 (fr)
BR (1) BRPI0720419A2 (fr)
CA (1) CA2672692A1 (fr)
CO (1) CO6210727A2 (fr)
RU (1) RU2009127883A (fr)
UY (1) UY30835A1 (fr)
WO (1) WO2008077557A1 (fr)
ZA (1) ZA200902187B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781657B1 (fr) 2004-02-14 2013-03-27 GlaxoSmithKline Intellectual Property Development Limited Medicaments ayant une activite sur le recepteur hm74a
WO2011101861A1 (fr) 2010-01-29 2011-08-25 Msn Laboratories Limited Procédé de préparation d'inhibiteurs de la dpp-iv
EP2465859A1 (fr) 2010-12-08 2012-06-20 Life & Brain GmbH Dérivés de 8-triazolylxanthine, leurs procédés de production et leur utilisation en tant qu'antagonistes du récepteur de l'adénosine
US9221821B2 (en) * 2012-06-05 2015-12-29 Forest Laboratories Holdings, Limited Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds
GB201311107D0 (en) * 2013-06-21 2013-08-07 Univ Edinburgh Bioorthogonal methods and compounds
TWI574691B (zh) 2013-07-18 2017-03-21 Taiho Pharmaceutical Co Ltd Anti - tumor agents for intermittent administration of FGFR inhibitors
WO2015008844A1 (fr) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Agent thérapeutique pour un cancer résistant à un inhibiteur de fgfr
WO2016159746A1 (fr) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Nouvelles éthynylxanthines, leur préparation et leur utilisation en tant qu'inhibiteurs de métalloprotéinases matricielles et d'angiogenèse
CA2989161C (fr) * 2015-03-27 2022-03-01 Latvian Institute Of Organic Synthesis Ethynylxanthines, leurs preparations et leurs utilisations pour traiter le cancer
GB2553686B (en) * 2015-03-27 2020-06-03 Latvian Inst Organic Synthesis Ethynylxanthines, preparation and use as calcium ion channel modulators
MY196077A (en) 2015-03-31 2023-03-13 Taiho Pharmaceutical Co Ltd Crystal Of 3,5-Disubstituted Benzene Alkynyl Compound
ES2828574T3 (es) * 2015-04-08 2021-05-26 Lewis And Clark Pharmaceuticals Inc Carbamatos de alquinilo sustituidos con xantina/carbamatos inversos como antagonistas de A2B
US11975002B2 (en) 2016-03-04 2024-05-07 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3769765B1 (fr) 2018-03-19 2024-04-17 Taiho Pharmaceutical Co., Ltd. Composition pharmaceutique comprenant du sulfate d'alkyle de sodium
US20240002416A1 (en) 2020-10-15 2024-01-04 Rheinische-Friedrich-Wilhelms-Universität Bonn MRGPRX4 Agonists and Antagonists
CN115636831A (zh) * 2022-10-27 2023-01-24 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
DE69526822T2 (de) * 1994-02-23 2003-01-23 Kyowa Hakko Kogyo Kk Xanthin-derivate
MXPA01010143A (es) 1999-04-09 2003-07-14 Cell Therapeutics Inc Derivados de xantina y analogos como inhibidores de transmision de senales celulares.
CA2433778A1 (fr) 2001-02-14 2002-08-22 William Glen Harter Derives de thieno'2,3-d pyrimidinone utilises comme inhibiteurs de metalloproteinases matricielles
HU230382B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
WO2004014916A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs bicycliques condenses de metalloproteinases de type pyrimidine
EP1633756B1 (fr) 2003-04-09 2008-12-24 Biogen Idec MA Inc. Antagonistes de recepteur d'adenosine a2a
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
EP1740587A4 (fr) 2004-04-02 2009-07-15 Adenosine Therapeutics Llc Antagonistes selectifs des recepteurs a-2a-de l'adenosine
WO2006091896A2 (fr) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Xanthines substituees par pyridyle
WO2006091898A2 (fr) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Xanthines substituees par pyrazolyle
WO2006091936A2 (fr) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Procedes permettant d'effectuer la synthese de xanthines a substitution cycloalkyle dissymetrique
US7579348B2 (en) 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines

Also Published As

Publication number Publication date
UY30835A1 (es) 2008-07-31
AR064657A1 (es) 2009-04-15
CO6210727A2 (es) 2010-10-20
US20080221134A1 (en) 2008-09-11
EP1939197A1 (fr) 2008-07-02
BRPI0720419A2 (pt) 2013-12-31
CA2672692A1 (fr) 2008-07-03
US8044061B2 (en) 2011-10-25
EP2097415A1 (fr) 2009-09-09
RU2009127883A (ru) 2011-01-27
CN101631788A (zh) 2010-01-20
EP2097415B1 (fr) 2014-10-29
WO2008077557A1 (fr) 2008-07-03
AU2007338413A1 (en) 2008-07-03
WO2008077557A8 (fr) 2009-05-22

Similar Documents

Publication Publication Date Title
ZA200902187B (en) 8-Ethinylxanthine derivatives as selective A2A receptor antagonists
IL195006A0 (en) Thiazolo-pyramidine/pyridine urea derivatives as adenosine a2b receptor antagonists
ZA200901036B (en) Adenosine derivatives as A2A receptor agonists
IL201234A0 (en) Adenosine a2a receptor antagonists
IL190336A0 (en) Imidazopyridine derivatives as a2b adenosine receptor antagonists
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
EP2058304A4 (fr) Antagoniste du récepteur p2x4
IL194398A0 (en) Bisadenosine compounds as adenosine a2a receptor agonists
HK1136302A1 (en) Progesterone receptor antagonists
EP2032797A4 (fr) Antagonistes du récepteur de l'adénosine a2b
SI2069310T1 (sl) Sulfonilpirazolin-1-karboksamidinski derivati kot 5-HT6 antagonisti
ZA200806065B (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
ZA200903574B (en) 2-Phenyl-6-Aminocarbonyl-Pyrimidine derivatives and their use as P2Y12 Receptor antagonists
IL196536A0 (en) Selective antagonists of a2a adenosine receptors
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
HUP0501169A2 (en) New phenantridine derivatives as selective bradykinin b1 receptor antagonists
ZA200903496B (en) Spiro-piperidine derivatives as via receptor antagonists
ZA200900627B (en) Selective antagonists of A2A adenosine receptors
GB0605861D0 (en) A2B adenosine receptor antagonists
GB0705379D0 (en) A2b adenosine receptor antagonists
GB0505786D0 (en) A2b adenosine receptor antagonists
ZA200603486B (en) Arylindenopyridines and arylindenopyridines and their use as adenosine A2a receptor antagonist
ZA200800516B (en) Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as V1a receptor antagonists